Compare JG & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JG | XLO |
|---|---|---|
| Founded | 2012 | 2016 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.4M | 41.8M |
| IPO Year | 2018 | 2021 |
| Metric | JG | XLO |
|---|---|---|
| Price | $6.70 | $0.70 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $2.00 |
| AVG Volume (30 Days) | 5.1K | ★ 492.2K |
| Earning Date | 11-13-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $50,967,244.00 | $31,804,000.00 |
| Revenue This Year | $10.90 | $626.78 |
| Revenue Next Year | N/A | $79.08 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 20.78 | ★ 588.40 |
| 52 Week Low | $5.75 | $0.62 |
| 52 Week High | $20.94 | $1.70 |
| Indicator | JG | XLO |
|---|---|---|
| Relative Strength Index (RSI) | 52.23 | 53.18 |
| Support Level | $6.16 | $0.63 |
| Resistance Level | $6.59 | $0.68 |
| Average True Range (ATR) | 0.29 | 0.03 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 78.91 | 81.30 |
Aurora Mobile Ltd provides stable, and accurate developer services for educational and medical products. It is focused on providing companies with stable and efficient push notification services. It provides a comprehensive suite of services to mobile app developers in mainland China. Through its developer services, it gains access to, aggregate, cleanse, structure and encrypt vast amounts of real-time and anonymous device-level mobile behavioral data. It offers data services such as iAPP which helps the investors to analyze opportunities in the sector, Anti-fraud helps to identify fraud risks, iAudience, iZone and other related services. The company operates and generates its revenue from the People's Republic of China.
Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies and immune cell engagers.